Literature DB >> 21976406

The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis.

Rose Gelineau-Morel1, Valentina Tomassini, Mark Jenkinson, Heidi Johansen-Berg, Paul M Matthews, Jacqueline Palace.   

Abstract

Previous imaging studies assessing the relationship between white matter (WM) damage and matter (GM) atrophy have raised the concern that Multiple Sclerosis (MS) WM lesions may affect measures of GM volume by inducing voxel misclassification during intensity-based tissue segmentation. Here, we quantified this misclassification error in simulated and real MS brains using a lesion-filling method. Using this method, we also corrected GM measures in patients before comparing them with controls in order to assess the impact of this lesion-induced misclassification error in clinical studies. We found that higher WM lesion volumes artificially reduced total GM volumes. In patients, this effect was about 72% of that predicted by simulation. Misclassified voxels were located at the GM/WM border and could be distant from lesions. Volume of individual deep gray matter (DGM) structures generally decreased with higher lesion volumes, consistent with results from total GM. While preserving differences in GM volumes between patients and controls, lesion-filling correction revealed more lateralised DGM shape changes in patients, which were not evident with the original images. Our results confirm that WM lesions can influence MRI measures of GM volume and shape in MS patients through their effect on intensity-based GM segmentation. The greater effect of lesions at increasing levels of damage supports the use of lesion-filling to correct for this problem and improve the interpretability of the results. Volumetric or morphometric imaging studies, where lesion amount and characteristics may vary between groups of patients or change over time, may especially benefit from this correction.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21976406      PMCID: PMC5435105          DOI: 10.1002/hbm.21402

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  41 in total

1.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm.

Authors:  Y Zhang; M Brady; S Smith
Journal:  IEEE Trans Med Imaging       Date:  2001-01       Impact factor: 10.048

2.  Quantitative trait Loci analysis using the false discovery rate.

Authors:  Yoav Benjamini; Daniel Yekutieli
Journal:  Genetics       Date:  2005-06-14       Impact factor: 4.562

3.  A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes.

Authors:  Antonia Ceccarelli; Maria A Rocca; Elisabetta Pagani; Bruno Colombo; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  Neuroimage       Date:  2008-04-20       Impact factor: 6.556

4.  A Bayesian model of shape and appearance for subcortical brain segmentation.

Authors:  Brian Patenaude; Stephen M Smith; David N Kennedy; Mark Jenkinson
Journal:  Neuroimage       Date:  2011-02-23       Impact factor: 6.556

5.  'Gender gap' in multiple sclerosis: magnetic resonance imaging evidence.

Authors:  C Pozzilli; V Tomassini; F Marinelli; A Paolillo; C Gasperini; S Bastianello
Journal:  Eur J Neurol       Date:  2003-01       Impact factor: 6.089

Review 6.  Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models.

Authors:  Hans Lassmann
Journal:  Exp Neurol       Date:  2009-10-17       Impact factor: 5.330

7.  Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.

Authors:  Deepa Preeti Ramasamy; Ralph H B Benedict; Jennifer L Cox; David Fritz; Nadir Abdelrahman; Sara Hussein; Alireza Minagar; Michael G Dwyer; Robert Zivadinov
Journal:  J Neurol Sci       Date:  2009-02-06       Impact factor: 3.181

Review 8.  Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.

Authors:  Frederik Barkhof; Peter A Calabresi; David H Miller; Stephen C Reingold
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

9.  Deep gray matter atrophy in multiple sclerosis: a tensor based morphometry.

Authors:  Guozhi Tao; Sushmita Datta; Renjie He; Flavia Nelson; Jerry S Wolinsky; Ponnada A Narayana
Journal:  J Neurol Sci       Date:  2009-01-24       Impact factor: 3.181

Review 10.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.

Authors:  David H Miller; Frederik Barkhof; Joseph A Frank; Geoffrey J M Parker; Alan J Thompson
Journal:  Brain       Date:  2002-08       Impact factor: 13.501

View more
  49 in total

1.  White Matter Segmentation Algorithm for DTI Images Based on Super-Pixel Full Convolutional Network.

Authors:  Yiping Mu; Qi Li; Yang Zhang
Journal:  J Med Syst       Date:  2019-08-12       Impact factor: 4.460

2.  Volumetric and shape analysis of thalamus in idiopathic generalized epilepsy.

Authors:  Ji Hyun Kim; Jung Bin Kim; Woo-Keun Seo; Sang-Il Suh; Seong-Beom Koh
Journal:  J Neurol       Date:  2013-03-20       Impact factor: 4.849

3.  White matter tract network disruption explains reduced conscientiousness in multiple sclerosis.

Authors:  Tom A Fuchs; Michael G Dwyer; Amy Kuceyeski; Sanjeevani Choudhery; Keith Carolus; Xian Li; Matthew Mallory; Bianca Weinstock-Guttman; Dejan Jakimovski; Deepa Ramasamy; Robert Zivadinov; Ralph H B Benedict
Journal:  Hum Brain Mapp       Date:  2018-05-08       Impact factor: 5.038

4.  Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Authors:  E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; I Paunkoski; D P Ramasamy; D Silva; E Carl; D Hojnacki; C Kolb; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2018-11-22       Impact factor: 3.825

5.  Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study.

Authors:  Niels Bergsland; Ferdinand Schweser; Michael G Dwyer; Bianca Weinstock-Guttman; Ralph H B Benedict; Robert Zivadinov
Journal:  Hum Brain Mapp       Date:  2018-06-19       Impact factor: 5.038

6.  The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.

Authors:  Isabela T Borges; Colin D Shea; Joan Ohayon; Blake C Jones; Roger D Stone; John Ostuni; Navid Shiee; Henry McFarland; Bibiana Bielekova; Daniel S Reich
Journal:  Mult Scler Relat Disord       Date:  2013-04-01       Impact factor: 4.339

7.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

8.  Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption.

Authors:  Kira Ashton; Tom A Fuchs; Devon Oship; Robert Zivadinov; Dejan Jakimovski; Niels Bergsland; Deepa P Ramasamy; Caila Vaughn; Bianca Weinstock-Guttman; Ralph H B Benedict; Michael G Dwyer
Journal:  J Neurol       Date:  2020-08-04       Impact factor: 4.849

9.  Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis.

Authors:  E Mak; N Bergsland; M G Dwyer; R Zivadinov; N Kandiah
Journal:  AJNR Am J Neuroradiol       Date:  2014-07-31       Impact factor: 3.825

10.  Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis.

Authors:  E Ghione; N Bergsland; M G Dwyer; J Hagemeier; D Jakimovski; D P Ramasamy; D Hojnacki; A A Lizarraga; C Kolb; S Eckert; B Weinstock-Guttman; R Zivadinov
Journal:  AJNR Am J Neuroradiol       Date:  2020-08-06       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.